leisure time -WSS

leisure time

author：leisure time 2025-10-02 21:35:44 - browse：8

Adam's take main illustration — Molly Ferguson/STAT

Thoughts about Cytokinetics after Wednesday night’s financing announcement:

1. Management is raising $500 million at $51 per share, when the stock was at $45 per share before the aficamtem study readout in December. That’s shocking. Somehow, management has not only removed all the M&A premium from the stock, but much or most of aficamtem’s value, too.

2. Omecamtiv’s resurrection: Are you kidding me? No one thinks bringing back this heart failure drug is a good idea, except management. Making it worse, the terms of the Royalty Pharma loan are, again, shocking. All the risk is borne by Cytokinetics. Royalty, in fact, may do better if omecamtiv fails.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Kaiser Permanente unions announce official strike date

WSS

FDA authorizes Novavax’s updated Covid

Menendez indictment could see pharma lose a key ally

AI can decode, harness the power of the humane immune system

The future of health care in the House

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

FDA rejects Alnylam's heart disease treatment over insufficient data

entertainment

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

explore

Apple is now the first public company to be valued at $3 trillion

After a drawn out lobbying fight, ARPA

Drug repurposing or repositioning? The language matters

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

Guidelines to prevent youth baseball injuries need more muscle

Inequities make cancer less preventable for women: report

Novavax promises a turnaround & Lilly roils the obesity market

The future of health care in the House

Jerome Adams on the need for new antivirals for Covid

Sana to lay off nearly a third of staff, de

focus

Phenylephrine and the overlooked value of the placebo effect

Intercept Pharmaceuticals sells itself for less than $1 billion

FDA seeks to regulate lab

How one patient went off dialysis — and others can too

Mindstrong's demise and the future of mental health care

Histogen: Failed biotech offers rare public look inside

entertainment

Wikipedia

entertainment

entertainment